Jay Lichter - 13 Sep 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
10%+ Owner
Signature
/s/ Jay B. Lichter
Issuer symbol
JANX
Transactions as of
13 Sep 2024
Transactions value $
-$112,133
Form type
4
Filing time
24 Oct 2024, 16:15:07 UTC
Previous filing
28 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Options Exercise $31.8K +1.87K +26.69% $17.00 8.87K 13 Sep 2024 Direct
transaction JANX Common Stock Options Exercise $8.35K +778 +8.77% $10.73 9.65K 13 Sep 2024 Direct
transaction JANX Common Stock Options Exercise $10.3K +778 +8.07% $13.22 10.4K 13 Sep 2024 Direct
transaction JANX Common Stock Options Exercise $15.6K +391 +3.75% $39.80 10.8K 13 Sep 2024 Direct
transaction JANX Common Stock Sale -$178K -3.82K -35.28% $46.68 7K 13 Sep 2024 Direct
holding JANX Common Stock 2.96M 13 Sep 2024 By Avalon Ventures XI, L.P. F1
holding JANX Common Stock 573K 13 Sep 2024 By Avalon BioVentures I, LP F2
holding JANX Common Stock 3.02M 13 Sep 2024 By Avalon BioVentures SPV I, L.P. F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -1.87K -6.44% $0.00 27.1K 13 Sep 2024 Common Stock 1.87K $17.00 Direct F4
transaction JANX Stock Option (right to buy) Options Exercise $0 -778 -6.44% $0.00 11.3K 13 Sep 2024 Common Stock 778 $10.73 Direct F4
transaction JANX Stock Option (right to buy) Options Exercise $0 -778 -6.44% $0.00 11.3K 13 Sep 2024 Common Stock 778 $13.22 Direct F4
transaction JANX Stock Option (right to buy) Options Exercise $0 -391 -4.84% $0.00 7.68K 13 Sep 2024 Common Stock 391 $39.80 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jay Lichter is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F2 The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3 The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F4 Immediately exercisable.

Remarks:

The number of securities reported in Column 5 of Table I and Column 9 of Table II represent the number of securities beneficially owned immediately following the transactions reported herein and do not reflect transactions that occurred on dates subsequent to the transactions reported herein. Form 4s filed by the reporting person on September 30, 2024 and October 18, 2024 are deemed amended hereby to give effect to the transactions effected on September 13, 2024 reported herein.